期刊
NEUROBIOLOGY OF AGING
卷 27, 期 9, 页码 1202-1211出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.neurobiolaging.2005.06.005
关键词
Alzheimer's disease; non-Alzheimer dementias; dementia; psychiatric disorders; depression; schizophrenia; cerebrospinal fluid; tau; phosphorylated tau; beta-amyloid(42); random sample
We prospectively evaluated the diagnostic accuracy of cerebrospinal fluid (CSF)-beta-antyloid(1-42) (A beta(42)), -total-tau (tau) and -phosphorylated-tau(181) (p-tau,81) as measured by sandwich ELISAs in the clinical routine of a community state hospital to discriminate between patients with Alzheimer's disease (AD), healthy controls (HQ, non-AD-dementias,a group composed of various psychiatric disorders (non-AD-dementias, mental diseases) and an age-matched random sample (RS) (total N = 219). By comparing patients with AD to HC as reference, tau revealed sensitivity (sens)/specificity (spec) of 88%/80%, p-tau(181) 88%/80%, tau/A beta(42)-ratio 81%/85% and phospho-tau(181)/A beta(42)-ratio 81%/78%. Discriminative power between HC and all dementias under investigation was estimated lower for tau (78%/77%) and p-tau(181) (73%/79%). Relative to patients with AD, ROC analysis for the RS revealed highest sens/spec for p-tau(181) (79%/77%) and p-tau(181)/A beta(42) ratio (78%/75%). Differentiation between AD versus a group made of patients with various psychiatric disorders was optimised by using CSF-p-tau(181) (80%/77%). Under clinical routine conditions current CSF-biomarkers show a substantial capacity to discriminate between AD and HC as reference and to mark off AD patients from RS and heterogeneous diagnostic groups composed of non-AD dementias and other psychiatric conditions. Despite a residual substantial overlap between the groups, we conclude that current CSF markers are well suited to support AD-related diagnostic procedures in every-day clinics. (c) 2005 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据